Assessing the U.S. Medical Innovation System

Why It Matters

Understanding and correcting risk aversion in NIH peer review is crucial for ensuring that groundbreaking medical discoveries receive the support needed to maintain U.S. leadership in health innovation.

Key Takeaways

• Peer review may discourage high‑risk biomedical research projects.
• NIH grant renewals used to measure risk‑taking impact.
• Evidence shows risk‑taking correlates with lower renewal probabilities.
• Researchers would pursue riskier agendas if funding constraints eased.
• Policy reforms could balance novelty with accountability in grant reviews.

Summary

The NBER‑sponsored event titled “Assessing the U.S. Medical Innovation System” convened economists, health‑policy scholars, and industry experts to examine how public funding mechanisms shape biomedical research. Organizers highlighted the central question: does the NIH peer‑review process penalize investigators who pursue high‑risk, high‑reward science? By focusing on NIH R01 grant renewals from 1980‑2015, the panel sought an empirical proxy for peer‑review attitudes toward risk.

Presenters, notably Wes Greenblatt and Pierre, reported that grants exhibiting greater methodological novelty or speculative aims were less likely to secure renewal, even after controlling for institution, investigator productivity, and grant characteristics. The analysis relied on linking funded publications to grant identifiers, allowing a direct assessment of the risk embedded in the funded work rather than an investigator’s overall portfolio. Results consistently showed a negative association between measured risk‑taking and renewal probability, suggesting that peer reviewers may favor incremental science.

The discussion invoked historical anecdotes, such as Nobel laureate Roger Kornberg’s testimony that his breakthrough RNA work would not receive funding today because reviewers could not foresee its impact. Participants also cited a pandemic‑era survey where most funded scientists indicated they would shift toward more ambitious, riskier projects if funding constraints were relaxed. These qualitative insights reinforced the quantitative findings, underscoring a systemic bias toward safety.

If the peer‑review system continues to suppress bold inquiry, the United States risks ceding leadership in transformative medical breakthroughs. Policymakers may need to redesign review criteria, introduce dedicated high‑risk funding streams, or adjust scoring to reward novelty without compromising accountability. Such reforms could rejuvenate the pipeline of disruptive therapies and sustain the nation’s biomedical competitiveness.